Pharma R&D ROI Spikes in 2023 as ‘Breakthroughs’ Re-Energize Industry: Report 4/29/2024

What’s Next for Obesity Therapeutics? Higher Quality Weight Loss 4/29/2024

As Autism Cases Rise, Biopharma Springs Into Action 4/29/2024

5 Mid-Stage ALS Drugs to Watch 4/29/2024

Opinion: Larimar Could Compete with Biogen in Friedreich’s Ataxia 4/29/2024

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test.

AbbVie Raises 2024 Profit Outlook, Reports Strong Q1 Sales for Skyrizi and Rinvoq 4/26/2024

Pfizer Secures FDA Approval for Hemophilia B Gene Therapy, Launches Warranty 4/26/2024

Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline 4/26/2024

GSK Sues Pfizer and BioNTech Over Alleged COVID-19 Patent Infringement 4/26/2024

Cigna’s Evernorth to Offer Humira Biosimilar with No Out-of-Pocket Cost 4/26/2024

BMS Decision to Lay Off 2,200 Employees Comes After M&A Spending Spree 4/26/2024

Tessera Cuts Dozens of Jobs Following Positive Preclinical Results 4/26/2024

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the AB-1002 program. AB-1002 is an investigational one-time gene therapy that is administered to the heart with the intention of helping to promote the production of a constitutively active form of protein inhibitor 1 (I-1c) designed to block the action of protein phosphatase 1.

BMS to Cut 2,200 Jobs in $1.5B Restructuring as Opdivo Sales Drop in Q1 4/25/2024

Merck Gets Q1 Beat as Sales of Cancer Blockbuster Keytruda Jump 20% 4/25/2024

Sanders Launches Probe of ‘Outrageously High Prices’ of Novo’s Ozempic, Wegovy 4/25/2024

Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery 4/25/2024

Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1 4/25/2024

FTC’s Noncompete Ban Makes Switching Biopharma Jobs Easier 4/25/2024